Xenon Pharmaceuticals Inc.
XENE Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$35.34
KIRA · Stoqly’s AI analyst, in plain words
- Xenon Pharmaceuticals Inc. had $7.5M of revenue in fiscal 2025. Over five years, revenue changed −25.3% a year on average.
- Its operating margin was −4,974.3%: of every 100 in sales, about −4,974 is left after running the business.
- Xenon Pharmaceuticals Inc. lost $346M in fiscal 2025.
- Free cash flow was −$280M in fiscal 2025, −3,732.2% of revenue.
Market cap
$3.5B
P/E
—
Revenue
$7.5M
Net income
−$346M
Free cash flow
−$280M
Operating margin
−4,974.3%
Xenon Pharmaceuticals Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−4,612.1%
No. It lost money last year.
Does profit turn into cash?
−3,732.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Xenon Pharmaceuticals Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Xenon Pharmaceuticals Inc.
- CIK
- 0001582313
Xenon Pharmaceuticals Inc. · XENE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $18.4M | $9.4M | $0.0M | $0.0M | $7.5M |
| Revenue growth | −42.7% | −48.8% | −100.0% | — | — |
| Operating margin | −428.4% | −1,368.9% | — | — | −4,974.3% |
| Net income | −$78.9M | −$125M | −$182M | −$234M | −$346M |
| Net margin | −427.8% | −1,328.9% | — | — | −4,612.1% |
| Diluted EPS | −$1.77 | −$2.06 | −$2.73 | −$3.01 | −$4.36 |
| Cash | |||||
| Cash from operations | −$69.5M | −$101M | −$151M | −$181M | −$279M |
| Capital expenditure | $2.1M | $2.9M | $5.6M | $3.1M | $0.8M |
| Free cash flow | −$71.6M | −$104M | −$157M | −$184M | −$280M |
| FCF margin | −388.1% | −1,101.6% | — | — | −3,732.2% |
| Share count change | 26.3% | 38.8% | 10.5% | 16.5% | 1.7% |
| Debt and strength | |||||
| Cash and short-term investments | $552M | $592M | $638M | $627M | $549M |
| Shareholders' equity | $550M | $721M | $928M | $755M | $582M |
| Current ratio | 39.0x | 26.4x | 23.6x | 17.8x | 13.4x |
| Returns and quality | |||||
| Return on equity | −21.9% | −19.7% | −22.1% | −27.8% | −51.8% |
| Return on tangible equity | −14.0% | −17.3% | −19.7% | −31.0% | −59.5% |
| Piotroski F-score | 3 | 1 | 1 | 1 | 2 |
| Altman Z'' | 29.6 | 25.0 | 26.9 | 17.2 | 6.9 |
Insiders bought, 12 months
$1.7M
2 insiders
Insiders sold, 12 months
$22.0M
6 insiders
Of sales under plans
97%
$21.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Xenon Pharmaceuticals Inc. · XENE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $35.34 a share, the company is worth $3.5B.
Source: SEC EDGAR XBRL filings (CIK 0001582313). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.